tbuckley/cabot-search huggingface dataset:
AB0062 Alteration of Tibial Metaphysis Area in NOD Mice Whit Sjögren's Syndrome
Authors: C.A. Gobbi, B. Busamia, M.B. Guglielmotti, S. Fontana, M.C. Mariani, K. Rhys, E. Albiero, M.A. Yorio
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Previously our group described in X-ray studies bone alterations in NOD mice affected with Sjögren9s syndrome (SS), characterized by the radiopacity decrease of the tibia cortical layers, compared to controls. These results would suggested that NOD mice with SS could developed disorders in tibial histological architecture. In the current literature, have not been described accurately bone disorders related to the SS. <h3>Objectives</h3> To assess histologically the tibial metaphysis area of non-obese diabetic mice with SS, compared to controls NOD without SS. <h3>Methods</h3> We used 10 NOD female mice with SS (group SS) and 10 controls NOD without SS (group C, control). They were cared in the animal facilities of the Faculty of chemistry of the UNC. At 4 months of age (weight 80 g ± 10) mice were anesthetized with ketamine-xylazine, both tibias were extracted, and then they were taken to euthanasia. The bones were fixed in formalin buffer, decalcified with EDTA and processed for its inclusion in paraffin; cuts were oriented to the longitudinal axis of the tibia. The samples obtained were stained with hematoxilin and eosin and was assessed qualitatively the tibial metaphysis area histology of both groups. <h3>Results</h3> In the SS group an histological architecture alteration was demonstrated in the cartilage and bone trabeculae, which less trabeculae, with less length, as well as sealing trabeculae, when they were compared to the C group. <h3>Conclusions</h3> The radiographic findings of the previous study in which it was observed a decrease in the tibial cortical bone density and the alterations in the histological architecture detected in the tibial metaphysis area in this qualitative preliminary study, we would suggest that NOD with SS mice generate changes in bone tissue. It9s necessary to carry out histomorphometric studies in 2D and immunostaining techniques of quality and activity of bone tissue, with the purpose of objectify the response in NOD mice with SS. <h3>References</h3> Gravani F, Papadaki I, Antypa E, Nezos A, Masselou K, Ioakeimidis D, Koutsilieris M, Moutsopoulos HM, Mavragani CP. Yin H, Cabrera-Perez J, Lai Z, Michael D, Weller M, Swaim WD, Liu X, Catalán MA, Rocha EM, Ismail N, Afione S, Rana NA, Di Pasquale G, Alevizos I, Ambudkar I, Illei GG, Chiorini JA El Ati Z, Fatma LB, Boulahya G, Rais L, Krid M, Smaoui W, Maiz HB, Beji S, Zouaghi K, Moussa FB <h3>Acknowledgement</h3> We are grateful whit Secyt subsidy UNC <h3>Disclosure of Interest</h3> None declared
Induction of Senescence by Doxorubicin Is Associated with Upregulated Mir-375 and Induction of Autophagy In CML Cell Line K562
Authors: Ming-Yu Yang, Wen-Chi Yang, Pai-Mei Lin, Jui-Feng Hsu, Hui-Hua Hsiao, Yi-Chang Liu, Hui-Jen Tsai, Sheng-Fung Lin
Journal: Blood (2010)
Vaccination with a New Generation of Fast Dendritic Cells Transfected with mRNA from hTERT, Survivin and Autologous Tumor Mount Strong Immune Responses and Prolong Survival
Authors: Iris Bigalke, Kirsti Honnashagen, Marianne Lundby, Julitta Kasten, Else Marit Suso Inderberg, Lisbeth Skoge, Stein Saboe-Larssen, Dolores J Schendel, Gunnar Kvalheim
Journal: Blood (2014)
Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkin’s Lymphoma.
Authors: Peter Borchmann, Raoul Herbrecht, Martin Wilhelm, Franck Morschhauser, Georg Hess, Klaus Kutz, Scott Stromatt, Andreas Engert
Journal: Blood (2006)
Patterns of Treatment for Newly Diagnosed and Relapsed/Refractory Peripheral T-Cell Lymphoma in the Community Setting
Authors: Tatyana Feldman, Michael McGuire, Claudio Faria, Andre Goy, Charles M. Farber, Kelly Choi, Jacqueline Connors, Dhakshila Paramanathan, Eric Schultz, Stuart L. Goldberg
Journal: Blood (2015)
Stimulation of TNF-α Production from Monocytes by Anti-Moesin Antibodies in the Serum of Patients with Aplastic Anemia: A Novel Mechanism of Myelosuppression by Autoantibodies.
Authors: Hiroyuki Takamatsu, Xingmin Feng, Xuzhang Lu, Tatsuya Chuhjo, Katsuya Okawa, Shinji Nakao
Journal: Blood (2006)
SP0084 Being Physical Active Is A Salvation? Men's Preferences for Physical Activity
Authors: B.A. Esbensen
Journal: Annals of the Rheumatic Diseases (2016)

Physical activity (PA) has been recommended as an essential part of the non-pharmacological management of inflammatory arthritis (IA). Among others, positive health effects of PA in IA have been demonstrated as improved cardiorespiratory fitness, muscle strength, mobility, physical functioning and quality of life. Also a reduction in disease activity, pain, fatigue and stiffness has been proved. While studies reveal inconsistent results on whether persons with IA are more or less physically active than their healthy counterparts, it has repeatedly been argued that people with IA engage in less PA at the higher intensities (moderate and vigorous) compared to healthy populations. Through previous qualitative research it has been suggested that men with IA, besides describing PA as an important strategy to manage their arthritis, also view engagement in PA an essential part of being a man. Thus, it could be argued that interventions or offers based on PA could be received as a legitimate form of health promoting activity responding to meet masculinity in needs and preferences among male patients with IA. Data from two qualitative studies focusing on men with IA will be presented as well as data from a cross-sectional study investigating physical activity behaviour, motivations, barriers and preferences for PA in men with IA. <h3>Disclosure of Interest</h3> None declared
miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1
Authors: Yuan Wang, Rachel Lieberman, Jing Pan, Qi Zhang, Meijun Du, Peng Zhang, Marja Nevalainen, Manish Kohli, Niraj K. Shenoy, Hui Meng, Ming You, Liang Wang
Journal: Molecular Cancer (2016)

Treatment options for metastatic castrate-resistant prostate cancer (mCRPC) are limited and typically are centered on docetaxel-based chemotherapy. We previously reported that elevated miR-375 levels were significantly associated with poor overall survival of mCRPC patients. In this study, we evaluated if miR-375 induced chemo-resistance to docetaxel through regulating target genes associated with drug resistance. We first compared miR-375 expression level between prostate cancer tissues and normal prostate tissues using data from The Cancer Genome Atlas (TCGA). To examine the role of miR-375 in docetaxel resistance, we transfected miR-375 using a pre-miRNA lentiviral vector and examined the effects of exogenously overexpressed miR-375 on cell growth in two prostate cancer cell lines, DU145 and PC-3. To determine the effect of overexpressed miR-375 on tumor growth and chemo-resistance in vivo, we injected prostate cancer cells overexpressing miR-375 into nude mice subcutaneously and evaluated tumor growth rate during docetaxel treatment. Lastly, we utilized qRT-PCR and Western blot assay to examine two miR-375 target genes, SEC23A and YAP1, for their expression changes after miR-375 transfection. By examining 495 tumor tissues and 52 normal tissues from TCGA data, we found that compared to normal prostate, miR-375 was significantly overexpressed in prostate cancer tissues (8.45-fold increase, p value = 1.98E-23). Docetaxel treatment induced higher expression of miR-375 with 5.83- and 3.02-fold increases in DU145 and PC-3 cells, respectively. Interestingly, miR-375 appeared to play a dual role in prostate cancer proliferation. While miR-375 overexpression caused cell growth inhibition and cell apoptosis, elevated miR-375 also significantly reduced cell sensitivity to docetaxel treatment in vitro, as evidenced by decreased apoptotic cells. In vivo xenograft mouse study showed that tumors with increased miR-375 expression were more tolerant to docetaxel treatment, demonstrated by greater tumor weight and less apoptotic cells in miR-375 transfected group when compared to empty vector control group. In addition, we examined expression levels of the two miR-375 target genes (SEC23A and YAP1) and observed significant reduction in the expression at both protein and mRNA levels in miR-375 transfected prostate cancer cell lines. TCGA dataset analysis further confirmed the negative correlations between miR-375 and the two target genes (r = −0.62 and −0.56 for SEC23A and YAP1, respectively; p < 0.0001). miR-375 is involved in development of chemo-resistance to docetaxel through regulating SEC23A and YAP1 expression. Our results suggest that miR-375 or its target genes, SEC23A or YAP1, might serve as potential predictive biomarkers to docetaxel-based chemotherapy and/or therapeutic targets to overcome chemo-resistance in mCRPC stage.
Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.
Authors: Annalisa Chiappella, Benedetta Puccini, Marianna Rossi, Simone Ferrero, Luca Arcaini, Ernesta Audisio, Ileana Baldi, Carola Boccomini, Barbara Botto, Fabbri Alberto, Chiara Frairia, Roberto Freilone, Marco Ladetto, Domenico Novero, Marco Paulli, Patrizia Pregno, Giorgio Priolo, Luigi Rigacci, Umberto Vitolo
Journal: Blood (2009)
Relapsed AML Patients with Mutational Shifts Harbor An Oligoclonal Primitive Cell Compartment at Presentation; Evidence for Clonal Selection towards Relapse
Authors: Costa Bachas, Gerrit Jan Schuurhuis, Zinia J. Kwidama, Angèle Kelder, Alexander N. Snel, Gertjan J. Kaspers, Jacqueline Cloos
Journal: Blood (2010)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Acute Lymphocytic Leukemia (ALL) in 126 Adults: Impact of Donor Source on Leukemia Free Survival (LFS).
Authors: Priya Kumar, Todd E. Defor, Claudio Brunstein, Juliet Barker, John E. Wagner, Daniel J. Weisdorf, Jeffrey S. Miller, Philip McGlave, Arne Slungaard, Mukta Arora, Marcie Tomblyn, Linda J. Burns
Journal: Blood (2005)
Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy
Authors: Javed Butler, Stephen E. Epstein, Stephen J. Greene, Arshed A. Quyyumi, Sergey Sikora, Raymond J. Kim, Allen S. Anderson, Jane E. Wilcox, Nikolai I. Tankovich, Michael J. Lipinski, Yi-An Ko, Kenneth B. Margulies, Robert T. Cole, Hal A. Skopicki, Mihai Gheorghiade
Journal: Circulation Research (2016)

Rationale: Potential benefits of mesenchymal stem cell (MSC) therapy in heart failure may be related to paracrine properties and systemic effects, including anti-inflammatory activities. If this hypothesis is valid, intravenous administration of MSCs should improve outcomes in heart failure, an entity in which excessive chronic inflammation may play a pivotal role. Objective: To assess the safety and preliminary efficacy of intravenously administered ischemia-tolerant MSCs (itMSCs) in patients with nonischemic cardiomyopathy. Methods and Results: This was a single-blind, placebo-controlled, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricular ejection fraction ≤40% and absent hyperenhancement on cardiac magnetic resonance imaging. Patients were randomized to intravenously administered itMSCs (1.5×10 6 cells/kg) or placebo; at 90 days, each group received the alternative treatment. Overall, 22 patients were randomized to itMSC (n=10) and placebo (n=12) at baseline. After crossover, data were available for 22 itMSC patients. No major differences in death, hospitalization, or serious adverse events were noted between the 2 treatments. Change from baseline in left ventricular ejection fraction and ventricular volumes was not significantly different between therapies. Compared with placebo, itMSC therapy increased 6-minute walk distance (+36.47 m, 95% confidence interval 5.98–66.97; P =0.02) and improved Kansas City Cardiomyopathy clinical summary (+5.22, 95% confidence interval 0.70–9.74; P =0.02) and functional status scores (+5.65, 95% confidence interval −0.11 to 11.41; P =0.06). The data demonstrated MSC-induced immunomodulatory effects, the magnitude of which correlated with improvement in left ventricular ejection fraction. Conclusions: In this pilot study of patients with nonischemic cardiomyopathy, itMSC therapy was safe, caused immunomodulatory effects, and was associated with improvements in health status and functional capacity. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02467387.
Evaluation of CD9 as a Candidate Leukemia Stem Cell Marker In Childhood Precursor B Cell Acute Lymphoblastic Leukemia
Authors: Noriko Satake, Astra Chang, Bridget McLaughlin, Sara Bauman, James Chan, Susmita Sarangi, Ping Zhou, Elaina Kenny, Liliya Kraynov, Sarah Arnott, Jeannine McGee, Jan A. Nolta
Journal: Blood (2010)
FRI0009 Serum 14-3-3 ETA Is An RA Specific Mechanistic Marker
Authors: B. Dasgupta, Y. Cherkas, S. Lamberth, K. Hayden, C. Brodmerkel, A. Marotta, M. Curran
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> 14–3-3η is an emerging soluble Rheumatoid Arthritis (RA) biomarker that activates intracellular pathways that lead to the upregulation of inflammatory and joint damage factors. It is reported to be highly specific and sensitive for RA as a diagnostic marker, higher levels are associated with greater joint damage progression risk and 14–3-3η9s modulation with treatment suggests a role in disease monitoring. <h3>Objectives</h3> In this study, we examine the specificity of 14–3-3η in an independent, clinically well-characterized cohort of moderate to severe RA and disease control subjects. <h3>Methods</h3> Serum 14–3-3η levels were measured in a total of 147 patients using the Augurex 14–3-3η ELISA. The patient set comprised 36 with RA and 111 controls consisting of 20 with asthma (A), 20 with Crohn9s Disease (CD), 12 presumed healthy (H), 16 with psoriasis (PsO), 20 with sarcoid arthritis (S), and 23 with spondylarthropathies (SpA). Sample testing was done independently of Augurex. Mann-Whitney testing together with Kruskal-Wallis analysis with the post-hoc Dunn9s multiple comparison test was performed to assess group differences. Receiver operator characteristic curve (ROC) analysis was performed to assess the specificity of 14–3-3η for RA. <h3>Results</h3> Median (IQR) serum 14–3-3η levels were significantly higher in RA [2.35ng/ml (0.28–19.41)] than all controls [0 (0–0)], p&lt;0.0001. ROC curve analysis further underscored this differential expression yielding a significant area under the curve (AUC) of 0.86, p&lt;0.0001. At the diagnostic positivity cut-off of ≥0.19 ng/ml, the ROC curve delivered a sensitivity of 81% with a corresponding specificity of 84%. Kruskal-Wallis testing revealed that serum 14–3-3η levels were significantly higher in RA in comparison to all other diseases, p&lt;0.0001. <h3>Conclusions</h3> Serum 14–3-3η is a highly specific RA biomarker. As a novel mechanistic disease factor, 14–3-3η is expected to provide new insights and approaches to RA management and clinical studies. <h3>References</h3> Arthritis Res Ther 2014; 16(2):R99; J Rheumatol 2014; 41(11):2104. <h3>Disclosure of Interest</h3> B. Dasgupta Employee of: Janssen R &amp; D, LLC, Y. Cherkas Employee of: Janssen R &amp; D, LLC, S. Lamberth Employee of: Janssen R &amp; D, LLC, K. Hayden Employee of: Janssen R &amp; D, LLC, C. Brodmerkel Employee of: Janssen R &amp; D, LLC, A. Marotta Grant/research support from: Janssen R &amp; D, LLC, M. Curran Employee of: Janssen R &amp; D, LLC
SAT0504 Prevalence and Correlates of Household Work Related Musculoskeletal Disorders in Low Back Region among Sri Lankan Housewives: Table 1.
Authors: P.D. Ranasinghe, I. Atukorala, A. Samaranayake, N.S. Gunawardana
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Household work is a significant cause of low back disorders particularly in the South Asian settings where work is manually performed and labour intensive. However, the prevalence household work related back pain in south Asian settings is unknown. <h3>Objectives</h3> To determine the prevalence of household work related musculoskeletal disorders (HWMSD) in low back region and its correlates among 20–50 year old housewives in an urban setting in Sri Lanka <h3>Methods</h3> A community based cross-sectional study was conducted on a sample of eligible housewives (n=1102) in an urban Sri Lankan setting using the multi-stage cluster sampling technique. Participants were women whose sole occupation was unpaid household work in their own homes for a minimum of 4 hours (continuously or intermittently) daily for at least 5 days a week, for a minimum of 2 years. Those with menopause, inflammatory arthritis, pregnant or in postpartum period, previous disability unrelated to household work were excluded. A novel validated tool- household work related musculoskeletal disorder questionnaire (HWMQ) with a sensitivity of 94.5% (91.7–97.3) and specificity of 99.3% (98.3–100) was used to identify HWMSD in low back. Correlates of HWMSD in low back region were conceptualized as physical exposures related to the housework, psychosocial factors and individual level factors. An analytical cross-sectional study using multivariate analyses comparing those with HWMSD of the low back region (n=397) and without HWMSD in any region of the body (n=405) determined the correlates of HWMSD in the low back region among housewives. <h3>Results</h3> The majority of housewives were performing multiple of household chores [cooking related activities (n=1031, 93.6%), hand washing clothes (n=811, 73.6%), ironing (n=972, 88.2%), sweeping indoor and outdoor (n=374, 33.9%), cleaning bathrooms/toilets (n=912, 82.8%), shopping (n=725, 65.8%) and carrying children (n=374, 33.9%)]. The prevalence of HWMSD in low back region among 20–50 year old housewives was 36% (95%CI: 33.1%&gt;39%). Correlates of HWMSD in low back region among 20–50 year old housewives identified as significant are shown in Table 1. <h3>Conclusions</h3> Prevalence of HWMSD in low back was high among housewives in Sri Lanka. The study identified several modifiable and a few non-modifiable physical exposures, psychosocial factors and individual level factors as significant correlates of HWMSD in low back region. <h3>Acknowledgement</h3> Medical Research Institute, Sri Lanka <h3>Disclosure of Interest</h3> None declared
AB1010 Achievement of Nice Quality Standards for Patients with New Presentation of Inflammatory Arthritis: Results from The Uk National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis
Authors: J. Ledingham, N. Snowden, J. Galloway, A. Rivett, J. Firth, E. Macphie, N. Kandala, I. Rowe, Z. Ide, E. Dennison
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The national audit office reported variation in the quality of services for patients with Inflammatory Arthritis (IA) in the UK in 2009. The Health Quality Improvement Partnership funded a national audit to explore this further. <h3>Objectives</h3> We set out to assesses whether trusts in England &amp; Wales are achieving the 7 quality standards (QS) published by the National Institute for Health &amp; Care Excellence (NICE). <h3>Methods</h3> All individuals &gt;16 years presenting to specialist rheumatology services in England &amp; Wales with suspected new onset IA were recruited. Clinician &amp; patient derived data were collected against all NICE QS over the 1st 3 months of specialist care. <h3>Results</h3> 6,354 patients were recruited nationally from 1 February 2014 to 31 January 2015. 94% of trusts/health submitted data. Patients were predominantly female (66%); white British (79%); and of working age (70%). At recruitment 46% had a diagnosis of Rheumatoid Arthritis (RA); 16% undifferentiated inflammatory arthritis (EIA). Only 17% of patients were referred by their general practitioner (GP) within 3 days of first presentation (QS1); median time interval 34 days. Over 25% waited &gt;3 months. 12% of referrals had no indication that EIA was suspected. Specialist assessment occurred &lt;3 weeks of referral for 38% (QS2). The median time interval was 4 weeks, &gt;25% of patients waited &gt;7 weeks. Higher staffing levels (&gt;1 consultant/100,000 population) &amp; the presence of EIA clinics were associated with shorter waiting times (odds ratio (95%CI) 1.3 (1.1–1.4) &amp; 1.6 (1.4–1.7) respectively). Disease modifying anti-rheumatic drug (DMARD) initiation within 6 weeks of referral (QS3) was achieved in 53% of RA patients; 36% were treated with combination DMARDs &amp; 82% with steroids. Clinicians reported that 59% of patients received structured education (QS4). Treat to target plans were set for 91% of patients. These targets were achieved in only 27% (QS5). Almost all trusts reported access to urgent advice (QS6) &amp; incorporated annual review services (QS7). <h3>Conclusions</h3> This audit has enabled English &amp; Welsh rheumatology services to measure their performance against NICE QS for the early management of IA &amp; RA, benchmarked to regional &amp; national comparators for the first time. The findings clearly demonstrate where improvement is needed. Delays in referral from primary care as well as delays in offering a first appointment in secondary care have been identified as key barriers to effective early arthritis care. <h3>Disclosure of Interest</h3> None declared
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3-ITD+ Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: Katherine Tarlock, Todd A. Alonzo, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Lillian Sung, Richard Aplenc, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2014)
Plerixafor+G-CSF-Mobilized Blood From Thalassemic Mice Provides High Yields Of Long-Term Repopulating Cells With Enhanced Engrafting Capacity : Implications For Human Stem Cell Gene Therapy
Authors: Nikoleta Psatha, Eleni Sgouramali, Athanasios Siametis, Elena Siapati, Panayotis Baliakas, Varnavas Constantinou, Achilles Anagnostopoulos, Thalia Papayannopoulou, George Stamatoyannopoulos, Evangelia Yannaki
Journal: Blood (2013)
Mir-23b Plays a Critical Role As a Tumor Suppressor miRNA In Multiple Myeloma
Authors: Mariateresa Fulciniti, Nicola Amodio, Rajya Bandi, Rao H. Prabhala, Sophia Adamia, Teresa Calimeri, Lavinia Biamonte, Marzia Leotta, Kenneth C. Anderson, Pierfrancesco Tassone, Munshi C Nikhil
Journal: Blood (2013)
Revisions to the Nutrition Facts Label
Authors: Susan T. Mayne, Douglas A. Balentine
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparative Effects of Wild Type and T315I Mutated bcr-ABL in Murine Embryonic Stem-Cell Derived Hematopoiesis.
Authors: Michael Melkus, Maria Theresa Mitjavila-Garcia, Marie-Laure Bonnet, Nathalie Sorel, Jean-Claude Chomel, Annelise Bennaceur-Griscelli, Ali G Turhan
Journal: Blood (2008)